DarioHealth unveils claims-free method to estimate healthcare savings

DarioHealth has presented research on a biometric-driven method for estimating healthcare cost savings and return on investment without waiting for medical claims data. The company says the approach translates changes in blood pressure, blood glucose and weight into projected expenditure reductions.
- DarioHealth presented its research at ISPOR Europe 2026.
- The model uses changes in blood pressure, blood glucose and weight.
- It estimates healthcare savings without waiting for medical claims data.
- DarioHealth says the approach can support purchasing and renewal decisions.
- The company says its platform uses more than 13 billion healthcare data points.
Model links biometric changes to projected savings
The research was presented at ISPOR Europe 2026, held November 8, 11 in Vienna, Austria. Titled “Estimating Individual-Level Medical Cost Savings from Digital Chronic Disease Management: A Biometric-to-PMPM Proxy Methodology,” the presentation was delivered by Yifat Hershcovitz, Ph.D., DarioHealth’s Vice President of Clinical and Scientific Affairs.
According to DarioHealth, the retrospective model uses observed changes in blood pressure, blood glucose and weight among members of digital chronic disease management programs. It then translates those changes into projected reductions in healthcare expenditures using published medical cost data.
The company describes the approach as transparent and replicable. It is designed to help health plans, employers and enterprise healthcare purchasers connect measurable clinical outcomes with estimated cost savings and ROI.
A way to assess value before claims data arrives
DarioHealth said medical claims data can take months to become available or may not be accessible. Its methodology is intended to provide evidence of program value without relying on claims analysis, giving customers information to support purchasing decisions, contract renewals and expansion into additional conditions and populations.
Erez Raphael, Chief Executive Officer of DarioHealth, said the study provides “an evidence-based and replicable method to demonstrate the in-year cost savings that Dario delivers specific to cardiometabolic disease.” He also said the research quantifies how savings are amplified when multiple conditions are enrolled.
“This research gives Dario clients a validated process to confirm that their investment in Dario for cardiometabolic health is delivering the cost savings they contracted for,” Raphael said, according to the company.
What the research could mean for DarioHealth customers
For healthcare purchasers, the methodology offers a proposed way to evaluate program performance and its potential financial impact during a period when medical claims data is delayed or unavailable. Hershcovitz said the model “bridges that gap directly by translating observed changes in clinical measures into transparent, evidence-based estimates of potential healthcare savings.”
DarioHealth said the research further demonstrates the economic value of its digital chronic disease management programs and supports new contract wins, contract renewals and expansion of existing customer relationships. Those uses, along with the methodology’s potential benefits and reliability, are forward-looking statements, and the company cautioned that actual results may differ significantly.
DarioHealth describes its platform as combining connected devices, personalized member engagement, AI-driven insights and provider-backed clinical care. It supports conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health needs. The company says its AI platform is powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade.

